Metanalysis of IBD studies finds combo biologics may have efficacy in refractor IBD. 279 IBD pts Rx w/ dual biologic or JAKi Rx . Most common = TNFi + anti-integrins (48%), ustekinumab & integrins (19%); remission seen in 59% & 34%, higher w/ EIM https://t.co/RReyRuNXck